Evidence map›Paper›PMID 40880639›Full record

ArticleFrontiers in pharmacology2025

Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research.

Russell Moreland, Abigail Arredondo, Anupam Dhasmana, Swati Dhasmana, Shabia Shabir, Asfia Siddiqua, Bonny Banerjee, Murali M Yallapu, Stephen W Behrman, Subhash C Chauhan and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Russell MorelandDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States.
Abigail ArredondoDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States.
Anupam DhasmanaDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States.
Swati DhasmanaDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States.
Shabia ShabirDepartment of Computer Science & Engineering, National Institute of Technology, Srinagar, India.
Asfia SiddiquaDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States.
Bonny BanerjeeInstitute for Intelligent Systems, and Department of Electrical and Computer Engineering, University of Memphis, Memphis, TN, United States.
Murali M YallapuDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States.
Stephen W BehrmanDepartment of Surgery, Baptist Memorial Medical Education, Memphis, TN, United States.
Subhash C ChauhanDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States.
Sheema KhanDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2025.1543112.].

Indexed as

biomarker discoverynew-onset diabetespancreatic cancerscreening strategiessocio-economic factors

Identifiers

PMID40880639
PMCPMC12381455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.